Plasma cell-free DNA methylation marks for episodic memory impairment: a pilot twin study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 08 2020
Historique:
received: 16 03 2020
accepted: 05 08 2020
entrez: 27 8 2020
pubmed: 28 8 2020
medline: 12 1 2021
Statut: epublish

Résumé

Decline in episodic memory performance usually causes the first clinical symptoms of Alzheimer's disease. At present, Alzheimer's disease can only be diagnosed at a very late stage when neurodegeneration and cognitive impairment is already irreversible. New early disease markers are needed for earlier and more efficient Alzheimer's disease intervention. To identify early disease markers, we implemented a genome-wide bisulphite sequencing method for the analysis of plasma cell-free DNA methylation profiles and compared differences associated with episodic memory performance in Finnish twin pairs. A noticeable amount of cell-free DNA was present in plasma, however, the amounts as well as the genomic coverage of these fragments varied substantially between individuals. We found no significant markers associated with episodic memory performance in the twins' plasma cell-free DNA methylation profiles. Furthermore, our results indicate that due to the low genomic coverage of cell-free DNA fragments and the variety in these fragments between individuals, the implemented genome-wide bisulphite sequencing method is not optimal for comparing cell-free DNA methylation differences between large groups of individuals.

Identifiants

pubmed: 32843700
doi: 10.1038/s41598-020-71239-9
pii: 10.1038/s41598-020-71239-9
pmc: PMC7447764
doi:

Substances chimiques

Cell-Free Nucleic Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14192

Références

Winblad, B. et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet. Neurol. 15, 455–532 (2016).
doi: 10.1016/S1474-4422(16)00062-4
Villemagne, V. L. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013).
doi: 10.1016/S1474-4422(13)70044-9
Konki, M. et al. Peripheral blood DNA methylation differences in twin pairs discordant for Alzheimer’s disease. Clin. Epigenet. 11, 130 (2019).
doi: 10.1186/s13148-019-0729-7
De Jager, P. L. et al. Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci. 17, 1156–1163 (2014).
doi: 10.1038/nn.3786
Smith, A. R. et al. A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. Neurobiol. Aging 74, 70–76 (2019).
doi: 10.1016/j.neurobiolaging.2018.09.024
Guo, S. et al. Identification of methylation haplotype blocks AIDS in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642 (2017).
doi: 10.1038/ng.3805
Sun, K. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl. Acad. Sci. USA 112, E5503–E5512 (2015).
doi: 10.1073/pnas.1508736112
Lun, F. M. et al. Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. Clin. Chem. 59, 1583–1594 (2013).
doi: 10.1373/clinchem.2013.212274
Delgado, P. O. et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumor Biol. 34, 983–986 (2013).
doi: 10.1007/s13277-012-0634-6
Sun, S. et al. Heritability estimation and differential analysis of count data with generalized linear mixed models in genomic sequencing studies. Bioinformatics 35, 487–496 (2019).
doi: 10.1093/bioinformatics/bty644
Song, Q. et al. A reference methylome database and analysis pipeline to facilitate integrative and comparative epigenomics. PLoS ONE 8, e81148 (2013).
doi: 10.1371/journal.pone.0081148
Pai, M. C., Kuo, Y. M., Wang, I. F., Chiang, P. M. & Tsai, K. J. The role of methylated circulating nucleic acids as a potential biomarker in Alzheimer’s disease. Mol. Neurobiol. 56, 2440–2449 (2019).
doi: 10.1007/s12035-018-1229-z
Järvenpää, T. et al. Characteristics of two telephone screens for cognitive impairment. Dement. Geriatr. Cogn. Disord. 13, 149–155 (2002).
doi: 10.1159/000048646
Kaprio, J. et al. The older Finnish twin cohort: 45 years of follow-up. Twin Res. Hum. Genet. 22, 240–254 (2019).
doi: 10.1017/thg.2019.54
Lindgren, N., Rinne, J. O., Palviainen, T., Kaprio, J. & Vuoksimaa, E. Prevalence and correlates of dementia and mild cognitive impairment classified with different versions of the modified Telephone Interview for Cognitive Status (TICS-m). Int. J. Geriatr. Psychiatry 34, 1883–1891 (2019).
doi: 10.1002/gps.5205
Ylikoski, R. The Relationship of Neuropsychological Functioning with Demographic Characteristics, Brain Imaging Findings, and Health in Elderly Individuals (Raija Ylikoski, Helsinki, 2000).
Sotaniemi, M. et al. CERAD-neuropsychological battery in screening mild Alzheimer’s disease. Acta Neurol. Scand. 125, 16–23 (2012).
doi: 10.1111/j.1600-0404.2010.01459.x
Jak, A. J. et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry 17, 368–375 (2009).
doi: 10.1097/JGP.0b013e31819431d5
Krueger, F. Babraham Bioinformatics: Trim Galore! (2012). https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ . (Accessed 4 Sept 2019)
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
doi: 10.1093/bioinformatics/btr167

Auteurs

M Konki (M)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland. miilko@utu.fi.
Turku Doctoral Programme of Molecular Medicine, University of Turku, 20014, Turku, Finland. miilko@utu.fi.

N Lindgren (N)

Drug Research Doctoral Program, University of Turku, 20014, Turku, Finland.
Turku PET Centre, University of Turku, 20520, Turku, Finland.

M Kyläniemi (M)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.

R Venho (R)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.

E Laajala (E)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.

B Ghimire (B)

Institute for Molecular Medicine Finland, University of Helsinki, 00014, Helsinki, Finland.

R Lahesmaa (R)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.

J Kaprio (J)

Institute for Molecular Medicine Finland, University of Helsinki, 00014, Helsinki, Finland.
Department of Public Health, University of Helsinki, 00271, Helsinki, Finland.

J O Rinne (JO)

Turku PET Centre, University of Turku, 20520, Turku, Finland.

R J Lund (RJ)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH